Skip to content
Agree.net – Lifestyle
Author:
Pyxis Oncology
Pyxis Oncology Announces Proposed Public Offering
September 29, 2026
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 9, 2026
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 8, 2026
Pyxis Oncology Appoints Thomas Civik CEO & Chairman
September 8, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences
September 1, 2026
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
August 13, 2026
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
June 30, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences
May 13, 2026
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
May 7, 2026
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
April 17, 2026
1
2
Next Page
→